MHDMF: Prediction of miRNA-disease associations based on Deep Matrix Factorization with Multi-source Graph Convolutional Network.

A growing number of works have proved that microRNAs (miRNAs) are a crucial biomarker in diverse bioprocesses affecting various diseases. As a good complement to high-cost wet experiment-based methods, numerous computational prediction methods have sprung up. However, there are still challenges that exist in making effective use of high false-negative associations and multi-source information for finding the potential associations.

Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study.

Background: Brigatinib is a next-generation anaplastic lymphoma kinase (ALK) inhibitor with demonstrated efficacy in locally advanced and metastatic non-small cell lung cancer (NSCLC) in crizotinib-refractory and ALK inhibitor-naive settings. This analysis assessed brigatinib in Asian vs. non-Asian patients from the first-line ALTA-1L trial.